Literature DB >> 15673421

Induction of angiogenesis and inhibition of apoptosis by hepatocyte growth factor effectively treats postischemic heart failure.

Vasant Jayasankar1, Y Joseph Woo, Timothy J Pirolli, Lawrence T Bish, Mark F Berry, Jeffrey Burdick, Timothy J Gardner, H Lee Sweeney.   

Abstract

BACKGROUND: Heart failure following myocardial infarction (MI) is a significant cause of morbidity and mortality and remains a difficult therapeutic challenge. Hepatocyte growth factor (HGF) is a potent angiogenic and anti-apoptotic protein whose receptor is upregulated following MI. This study was designed to investigate the ability of HGF to prevent heart failure in a rat model of experimental MI.
METHODS: The rats underwent direct intramyocardial injection with replication-deficient adenovirus encoding HGF (n = 7) or null virus as control (n = 7) 3 weeks following ligation of the left anterior descending coronary artery. Analysis of the following was performed 3 weeks after injection: cardiac function by pressure-volume conductance catheter measurements; LV wall thickness; angiogenesis by Von Willebrand's factor staining; and apoptosis by the TUNEL assay. The expression levels of HGF and the anti-apoptotic factor Bcl-2 were analyzed by Western blot.
RESULTS: Adeno-HGF-treated animals had greater preservation of maximum LV pressure (HGF 77 +/- 3 vs. control 64 +/- 5 mmHg, p < 0.05), maximum dP/dt (3024 +/- 266 vs. 1907 +/- 360 mmHg/sec, p < 0.05), maximum dV/dt (133 +/- 20 vs. 84 +/- 6 muL/sec, p < 0.05), and LV border zone wall thickness (1.98 +/- 0.06 vs. 1.53 +/- 0.07 mm, p < 0.005). Angiogenesis was enhanced (151 +/- 10.0 vs. 90 +/- 4.5 endothelial cells/hpf, p < 0.005) and apoptosis was reduced (3.9 +/- 0.3 vs. 8.2 +/- 0.5%, p < 0.005). Increased expression of HGF and Bcl-2 protein was observed in the Adeno-HGF-treated group.
CONCLUSIONS: Overexpression of HGF 3 weeks post-MI resulted in enhanced angiogenesis, reduced apoptosis, greater preservation of ventricular geometry, and preservation of cardiac contractile function. This technique may be useful to treat or prevent postinfarction heart failure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15673421     DOI: 10.1111/j.0886-0440.2005.200373.x

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


  19 in total

Review 1.  Adipose-derived stem cells for myocardial infarction.

Authors:  Manuel Mazo; Juan José Gavira; Beatriz Pelacho; Felipe Prosper
Journal:  J Cardiovasc Transl Res       Date:  2010-11-30       Impact factor: 4.132

2.  Safety and efficacy of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with critical limb ischemia.

Authors:  M R Kibbe; A T Hirsch; F O Mendelsohn; M G Davies; H Pham; J Saucedo; W Marston; W-B Pyun; S-K Min; B G Peterson; A Comerota; D Choi; J Ballard; R A Bartow; D W Losordo; W Sherman; V Driver; E C Perin
Journal:  Gene Ther       Date:  2015-12-08       Impact factor: 5.250

3.  Tissue-engineered pro-angiogenic fibroblast scaffold improves myocardial perfusion and function and limits ventricular remodeling after infarction.

Authors:  J Raymond Fitzpatrick; John R Frederick; Ryan C McCormick; David A Harris; Ah-Young Kim; Jeffrey R Muenzer; Alex J Gambogi; Jing Ping Liu; E Carter Paulson; Y Joseph Woo
Journal:  J Thorac Cardiovasc Surg       Date:  2010-04-03       Impact factor: 5.209

4.  Computational protein design to reengineer stromal cell-derived factor-1α generates an effective and translatable angiogenic polypeptide analog.

Authors:  William Hiesinger; Jose Manuel Perez-Aguilar; Pavan Atluri; Nicole A Marotta; John R Frederick; J Raymond Fitzpatrick; Ryan C McCormick; Jeffrey R Muenzer; Elaine C Yang; Rebecca D Levit; Li-Jun Yuan; John W Macarthur; Jeffery G Saven; Y Joseph Woo
Journal:  Circulation       Date:  2011-09-13       Impact factor: 29.690

5.  Myocardial transfection with naked DNA plasmid encoding hepatocyte growth factor prevents the progression of heart failure in dogs.

Authors:  Sharad Rastogi; Mayra Guerrero; Mengjun Wang; Itamar Ilsar; Michael S Sabbah; Ramesh C Gupta; Hani N Sabbah
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-01-07       Impact factor: 4.733

6.  Mathematically engineered stromal cell-derived factor-1α stem cell cytokine analog enhances mechanical properties of infarcted myocardium.

Authors:  John W MacArthur; Alen Trubelja; Yasuhiro Shudo; Philip Hsiao; Alexander S Fairman; Elaine Yang; William Hiesinger; Joseph J Sarver; Pavan Atluri; Y Joseph Woo
Journal:  J Thorac Cardiovasc Surg       Date:  2013-01       Impact factor: 5.209

Review 7.  Re-engineered stromal cell-derived factor-1α and the future of translatable angiogenic polypeptide design.

Authors:  William Hiesinger; Andrew B Goldstone; Y Joseph Woo
Journal:  Trends Cardiovasc Med       Date:  2012-08-16       Impact factor: 6.677

8.  Phase 1/2 open-label dose-escalation study of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with painful diabetic peripheral neuropathy.

Authors:  Senda Ajroud-Driss; Mark Christiansen; Jeffrey A Allen; John A Kessler
Journal:  Mol Ther       Date:  2013-04-23       Impact factor: 11.454

9.  Quantitative MR measurements of regional and global left ventricular function and strain after intramyocardial transfer of VM202 into infarcted swine myocardium.

Authors:  Marcus Carlsson; Nael F Osman; Philip C Ursell; Alastair J Martin; Maythem Saeed
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-06-06       Impact factor: 4.733

10.  Improvement of heart function in postinfarct heart failure swine models after hepatocyte growth factor gene transfer: comparison of low-, medium- and high-dose groups.

Authors:  Zhi-jian Yang; Bo Chen; Zhang Sheng; Ding-guo Zhang; En-zhi Jia; Wei Wang; Dong-chao Ma; Tie-bing Zhu; Lian-sheng Wang; Chun-jian Li; Hui Wang; Ke-jiang Cao; Wen-zhu Ma
Journal:  Mol Biol Rep       Date:  2009-08-13       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.